Pharma Focus Asia

Richter-Helm Expands with the Construction of New Manufacturing Facility

Introduction:

Richter-Helm invests US$83 million to construct new biological manufacturing facility. The facility will be located at cGMP manufacturing facility in Bovenau, Germany.

Features:

The manufacturing facility will support the production of high value biopharmaceutical products.

The site covers an area of 10,000 m² and consists of all necessary utilities and infrastructure, such as QC-labs, warehouse and technical areas.

Currently, there are two cGMP-compliant production facilities with bioreactor capacities ranging up to 1,500 litres located in Hannover and Bovenau, Germany.

The facility will triple the size of the existing production capacity and increase its current warehouse, laboratory, and administration buildings.

The new manufacturing facility will add two additional highly flexible and fully equipped production trains with interchangeable product flows. In addition, bioreactor capacities of 300 litres and 1,500 litres will be added.

The new facility is expected to start its full-scale operations and manufacturing by the end of 2023.

Specifications:

NameRichter-Helm
TypeNew Construction
BudgetUS$83 million
Year2023
magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference